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Abstract
To examine associations between lipohypertrophy and lipoatrophy and illicit drug use, smoking, and at-risk
alcohol use among a large diverse cohort of persons living with HIV (PLWH) in clinical care. 7,931 PLWH at
six sites across the United States completed 21,279 clinical assessments, including lipohypertrophy and li-
poatrophy, drug/alcohol use, physical activity level, and smoking. Lipohypertrophy and lipoatrophy were
measured using the FRAM body morphology instrument and associations were assessed with generalized
estimating equations. Lipohypertrophy (33% mild, 4% moderate-to-severe) and lipoatrophy (20% mild, 3%
moderate-to-severe) were common. Older age, male sex, and higher current CD4 count were associated with
more severe lipohypertrophy ( p values <.001–.03). Prior methamphetamine or marijuana use, and prior and
current cocaine use, were associated with more severe lipohypertrophy ( p values <.001–.009). Older age,
detectable viral load, and low current CD4 cell counts were associated with more severe lipoatrophy ( p values
<.001–.003). In addition, current smoking and marijuana and opiate use were associated with more severe
lipoatrophy ( p values <.001–.03). Patients with very low physical activity levels had more severe lipohyper-
trophy and also more severe lipoatrophy than those with all other activity levels ( p values <.001). For example,
the lipohypertrophy score of those reporting high levels of physical activity was on average 1.6 points lower
than those reporting very low levels of physical activity (-1.6, 95% CI: -1.8 to -1.4, p < .001). We found a high
prevalence of lipohypertrophy and lipoatrophy among a nationally distributed cohort of PLWH. While low
levels of physical activity were associated with both lipohypertrophy and lipoatrophy, associations with sub-
stance use and other clinical characteristics differed between lipohypertrophy and lipoatrophy. These results
support the conclusion that lipohypertrophy and lipoatrophy are distinct, and highlight differential associations
with specific illicit drug use.
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Introduction
Over the last two decades, there has been a significantdecline in HIV-related morbidity and mortality due to
antiretroviral therapy (ART).1,2 This has been accompanied
by an increase in the body morphology changes of lipohy-
pertrophy and lipoatrophy.3 While a decrease in body mor-
phology abnormalities over the next few years due to earlier
treatment and the use of less toxic antiretroviral medications
has been expected,4 only a small decrease in lipoatrophy as
measured by leg fat percentage has been seen in recent years.4
While lipohypertrophy and lipoatrophy are often conceptu-
alized as a single disorder called ‘‘lipodystrophy,’’ they are
distinct entities with different etiologies.5–7 Lipohypertrophy
is characterized by fat accumulation particularly an increase
in visceral fat in the abdomen, enlargement of the dorso-
cervical fat pad, and/or fat deposition in breast tissue.5,8,9
Lipoatrophy is characterized by loss of subcutaneous fat often
most pronounced on the face and extremities, with the legs
and gluteal region affected more than the upper body.5,6,8,10
Metabolic complications of HIV, including lipohyper-
trophy and lipoatrophy, have been associated with ART, HIV
infection itself, and other demographic and lifestyle fac-
tors such as age, sex, race/ethnicity, and sedentary lifestyle/
physical activity levels.3,7,8,11–15 Few studies have examined
the role of behavioral factors such as substance use, and in
particular, prior studies have not evaluated the independent
association between lipohypertrophy or lipoatrophy and al-
cohol, smoking, and illicit drug use, including the role of
individual drugs.5,6,16 Furthermore, behavioral factors such
as substance abuse, physical activity, and smoking are often
correlated with each other.17–19 Discerning the unique contri-
butions of at-risk alcohol use, smoking, and other substance
use will require considering these factors simultaneously.
We conducted this study to examine the associations be-
tween illicit drug use, smoking, and at-risk alcohol use and
lipohypertrophy and lipoatrophy among a large, diverse,
nationally distributed well-characterized cohort of persons
living with HIV (PLWH) in clinical care.
Methods
Study setting
This observational cohort study was conducted among the
Centers for AIDS Research Network of Integrated Clinical
Systems (CNICS) cohort. CNICS is a longitudinal observa-
tional study of PLWH from eight clinical sites receiving
primary care from 1/1/1995 to present.20
Study subjects
All PLWH 18 years of age or older who completed one
or more clinical assessments of patient-reported outcomes
(PROs) as part of a routine clinical visit before 11/2013 were
eligible for the study. The PRO clinical assessment was in-
tegrated into clinical care between 2006 and 2012 at six
participating CNICS sites. The study was approved by In-
stitutional Review Boards at each site.
Data sources
The CNICS data repository captures longitudinal data on
the CNICS cohort.20 The data repository integrates compre-
hensive clinical data from all outpatient and inpatient en-
counters, including standardized HIV-related information
collected at enrollment (initial clinic visit) regarding prior
ART history. Demographic, clinical, laboratory, and medi-
cation data are obtained from each site’s electronic health
record and other institutional data sources.
PLWH used tablet PCs with touch screens to complete
the clinical assessment every 4–6 months. The assessment
includes a morphology assessment that measures lipohyper-
trophy and lipoatrophy based on the Study of Fat Redis-
tribution and Metabolic Change instrument (FRAM), which
has been validated against objective imaging approaches
such as MRI5,6,21,22 and has key associations with relevant
metabolic outcomes such as hypertension, as well as other
clinical outcomes such as depression and quality of life.23,24
The assessment also includes drug use using a modified
Alcohol, Smoking, and Substance Involvement Screening
Test (ASSIST),25,26 alcohol use using the Alcohol Use Dis-
orders Identification Test consumption questions (AUDIT-
C),27,28 cigarette use, and physical activity using the Lipid
Research Clinic questionnaire.29 We used web-based survey
software developed specifically for PROs.30,31 Patients who
are medically unstable at the time of a visit, appear in-
toxicated, or do not speak English or Spanish are not asked to
complete the assessment. Given the slow rate of change of
body morphology, in 2012, the clinical assessment was pro-
grammed with a skip pattern such that it only gives the
FRAM body morphology instrument annually even though
they can take the assessment every 4–6 months.
Measurement of body morphology
The FRAM body morphology instrument asks PLWH to
rate changes in the amount of fat in specific body regions
graded on a 7-point scale ranging from -3 to +3 for each
region. No change was scored as 0; mild, moderate, and se-
vere increases were scored as +1, +2, and +3; and mild,
moderate, and severe decreases were scored as -1, -2, and
-3. An overall lipohypertrophy score was calculated totaling
all positive responses (indicating increases in size of body
regions). An overall lipoatrophy score was calculated totaling
all negative responses (indicating decreases in size).
We conducted analyses using three scoring methods for
body morphology. We examined lipohypertrophy and lipoa-
trophy categories (none, 0 points; mild, 1–12 points; and
moderate-to-severe, >12 points), and also continuous lipohy-
pertrophy and lipoatrophy scores. We also examined lipohy-
pertrophy and lipoatrophy as binary outcomes (none vs. any).
Measurement of substance use
There are several ways to score the ASSIST to measure
substance use.25,26 We used the ASSIST to operationally define
use of four individual drug classes (marijuana, crack/cocaine,
methamphetamines/crystal, and illicit opioids/heroin) and
categorized use as current (past 3 months), prior, or never.
We calculated AUDIT-C scores for current alcohol use by
summing the scores for each item (0–4 points each).27 We
used a score of ‡4 for men and ‡3 for women to define at-risk
alcohol consumption.32
We used responses to the cigarette items to categorize
PLWH as current smokers, past or ex-smokers, and non-
smokers.
Measurement of physical activity
This 4-item instrument classifies PLWH into very low active,
low active, moderately active, and highly active categories.29
Statistical analyses
We performed bivariate analyses comparing participant
characteristics to the overall cohort at the six participating
sites using chi-squared tests and t-tests. We similarly com-
pared demographic and clinical characteristics of those with
completed assessments and those with assessments excluded
due to missing body morphology or other information.
We examined associations between body morphology
abnormalities, demographic characteristics, clinical charac-
teristics, and behavioral factors. Demographic characteristics
included age, race/ethnicity, sex, and HIV transmission risk
factor. Clinical characteristics included CD4 count (current
and nadir), peak HIV-1 RNA level, current ART use, dura-
tion of exposure to stavudine/didanosine, body mass index
(BMI), and hepatitis C virus (HCV) status. BMI was mea-
sured as a continuous variable and as a categorical variable:
underweight <18.5 kg/m2, normal 18.5–24.9 kg/m2, over-
weight 25.0–29.9 kg/m2, and obese ‡30 kg/m2. Duration of
stavudine and/or didanosine was included as a key cause of
body morphology abnormalities, particularly lipoatrophy.33
Behavioral factors included current and past illicit drug use,
at-risk alcohol use, current and past smoking status, and
physical activity levels.
We used generalized estimating equations with an ex-
changeable correlation structure and robust standard errors to
assess differences in body morphology associated with al-
cohol, cigarette smoking, and other substance use, while
accounting for within-subject correlations between repeated
measures.34 Similarly, we used ordinal logistic regression
adjusting for repeated measures for categorical lipohyper-
trophy and lipoatrophy; however, these models failed the
assumption of proportional odds. We therefore repeated these
analyses using logistic regression with 2 models: one for mild
versus none, and the other for moderate-to-severe versus
none for categorical lipohypertrophy and lipoatrophy. We
conducted separate models for lipohypertrophy and lipoa-
trophy. We adjusted all analyses for age, race, sex, clinical
site, currently receiving ART, duration of prior stavudine/
didanosine, current and nadir CD4 cell count, viral load,
HCV, at-risk alcohol use, smoking status, physical activity
level, and current, past, or no substance use. We adjusted
models evaluating lipohypertrophy for lipoatrophy, and ad-
justed models evaluating lipoatrophy for lipohypertrophy.
We conducted sensitivity analyses by repeating models
limited to the subset of individuals known to be naive to ART
when they initiated care at a CNICS site to ensure accurate
capture of duration of didanosine/stavudine. We also con-
ducted sensitivity analyses focused on belly fat (as an ordinal
scale) instead of overall lipohypertrophy. Given the poten-
tially evolving nature of lipohypertrophy and lipoatrophy,4
we also considered sensitivity analyses with assessment of
calendar year. We considered two-tailed p-values <.05 to be
significant. We used Stata 13 for analyses.
Results
Clinical assessments were completed 21,279 times by
7,931 PLWH. An additional 2,749 assessments were ex-
cluded due to missing information on body morphology, al-
cohol, or substance use. The majority of these were due to
missing body morphology information as these items are
automatically skipped if the body morphology instrument
had been completed in the prior 364 days. There were no
demographic (age, race, and sex) or clinical differences (CD4
count) for patients from excluded and included assessments.
Table 1 describes demographic and clinical characteristics by
baseline body morphology at each initial assessment. Mean
age was 45 (SD 10), 87% were men, and mean current CD4
count was 523 cells/mm3 (Table 1). Demographic and clin-
ical characteristics of participants were similar to all indi-
viduals receiving care at the participating clinics during the
study period (data not shown).
Among all 21,279 assessments, no lipohypertrophy or li-
poatrophy was reported during 8,471 clinical assessments
(40%), mild lipohypertrophy was reported during 7,123 as-
sessments (33%), mild lipoatrophy was reported during 4,301
(20%) assessments, moderate-to-severe lipohypertrophy was
reported in 803 (4%) assessments, and moderate-to-severe
lipoatrophy was reported in 582 (3%) assessments. While
it is theoretically possible for an individual to have both
moderate-to-severe lipohypertrophy and moderate-to-severe
lipoatrophy in different regions, this was only reported dur-
ing two assessments. There were 157 assessments with
moderate-to-severe lipohypertrophy and mild lipoatrophy
(<1%), and 140 where individuals reported moderate-to-
severe lipoatrophy and mild lipohypertrophy (<1%). There
were 2,604 assessments where individuals reported both mild
lipohypertrophy and mild lipoatrophy (12%). Individuals
with both lipohypertrophy and lipoatrophy were categorized
according to whichever was more severe; in the case of a tie
(411 assessments, 1.9%), people were categorized as having
lipoatrophy.
Bivariate analyses at baseline, female sex, older age,
higher BMI, very low physical activity levels, and currently
receiving ART (Table 1) were associated with lipohyper-
trophy. In contrast, older age, lower current and nadir CD4
cell counts, lower BMI, and very low physical activity levels
were associated with lipoatrophy in bivariate analyses
(Table 1).
When we examined substance use, rates of baseline body
morphology category differed among PLWH who reported
never, prior, or current use of opiates, cocaine/crack, meth-
amphetamines, and marijuana ( p values<.001, w2). A con-
sistent pattern of body morphology was seen for only some
drugs (Table 2). Smoking, but not current at-risk alcohol use,
was associated with lipoatrophy and, in particular, current
smoking was associated with moderate-to-severe lipoatrophy.
Multivariate analyses
Older age, female sex, and higher current CD4 count were
all associated with more severe lipohypertrophy using con-
tinuous lipohypertrophy scores in adjusted analyses (p values
<.001–.03). In contrast, a higher CD4 cell count nadir and
more than very low levels of physical activity were associ-
ated with less severe lipohypertrophy (p values .001–.02)
(Fig. 1). For example, the lipohypertrophy score of those
reporting high levels of physical activity was on average 1.6
points lower than those reporting very low levels of physical
activity (-1.6, 95% CI: -1.8 to -1.4, p < .001).
In models adjusting for demographic and clinical factors,
prior methamphetamine use, prior and current cocaine use,
and prior marijuana use were all associated with more severe
lipohypertrophy using the continuous scale ( p values <.001–
.009), while current cigarette smoking was associated with
less severe lipohypertrophy ( p value .05) (Fig. 1). There was
no association with opiate or at-risk alcohol use.
Many of the same factors were associated with binary li-
pohypertrophy (any vs. none, Table 3, model 1) as an out-
come. In addition, black race was significantly associated
with being less likely to have lipohypertrophy compared with
white race, and current ART use was associated with lipo-
hypertrophy ( p < .001–0.02). For example, a higher current
CD4 cell count was associated with lipohypertrophy (CD4
Table 1. Demographic and Clinical Characteristics of Patients at Initial










N = 3,156 N = 2,607 N = 260 N = 1,664 N = 244
N % N % N % p value* N % N % p value**
Sex
Male 2760 87% 2240 86% 177 68% 153 92% 207 85%
Female 396 13% 367 14% 83 32% <.001 134 8% 37 15% <.001
Race
White 1538 49% 1486 57% 129 50% 942 57% 135 55%
Black 927 29% 602 23% 70 27% 353 21% 54 22%
Hispanic 531 17% 397 15% 52 20% 294 18% 45 18%
Other/Unknown 160 5% 122 5% 9 4% <.001 75 5% 10 4% <.001
Age (years)
<30 447 14% 224 9% 19 7% 178 11% 18 7%
30–39 800 25% 543 21% 44 17% 342 21% 31 13%
40–49 1144 36% 1092 42% 120 46% 671 41% 97 40%
‡50 765 24% 748 30% 77 30% <.001 473 28% 98 40% <.001
HIV transmission risk factor
MSM 1994 63% 1652 63% 135 52% 1114 67% 128 52%
IDU 308 10% 351 13% 37 14% 225 14% 34 14%
MSM & IDU 69 2% 61 2% 5 2% 42 3% 5 2%
Heterosexual 705 22% 471 18% 78 30% 236 14% 61 25%
Other/Unknown 80 3% 72 3% 5 2% <.001 47 3% 16 7% <.001
CD4+ cell count nadir (cells/mm3)
0–200 1456 46% 1254 48% 142 55% 790 47% 153 63%
201–350 897 28% 712 27% 50 19% 421 25% 49 20%
>350 803 25% 641 25% 68 26% .02 453 27% 42 17% <.001
CD4+ cell count current (cells/mm3)
0–200 427 14% 325 12% 34 13% 271 16% 84 34%
201–350 584 19% 440 17% 46 18% 294 18% 41 17%
>350 2145 68% 1842 71% 180 69% .3 1099 66% 119 49% <.001
Hepatitis C virus
No 2699 86% 2078 80% 211 81% 1328 80% 180 74%
Yes 457 14% 529 20% 49 19% <.001 336 20% 64 26% <.001
Physical Activity Level
Very low 575 18% 778 30% 111 43% 466 28% 117 48%
Low 1483 47% 1154 44% 111 43% 654 39% 79 32%
Moderate 613 19% 435 17% 29 11% 343 21% 30 12%
High 485 15% 240 9% 9 3% <.001 201 12% 18 7% <.001
BMI (N = 7,830)
<18.5 80 3% 13 <1% 8 3% 53 3% 28 11%
18.5–24.9 1351 43% 684 27% 33 13% 810 49% 151 62%
25–29.9 1285 41% 1278 50% 81 32% 624 38% 55 23%
‡30 440 14% 563 22% 134 52% <.001 149 9% 10 4% <.001
Currently receiving ART
Yes 2339 74% 2144 82% 223 86% 1341 81% 184 75%
No 817 26% 463 18% 37 14% <.001 323 19% 60 25% <.001
Individuals with both lipoatrophy and lipohypertrophy are categorized by the more severe body morphology.
*Chi2 of no body morphology versus mild lipohypertrophy versus moderate-to-severe lipohypertrophy.
**Chi2 of no body morphology versus mild lipoatrophy versus moderate-to-severe lipoatrophy.
MSM, men who have sex with men; IDU, injection drug user; BMI body mass index.
cell count 201–350, OR 1.2: 95% CI 1.1–1.4, p = .005; CD4
cell count >350 OR 1.4: 95% CI 1.2–1.6, p < .001 compared
to CD4 count £200) as was prior marijuana use compared
with no use (OR 1.3, 95% CI: 1.2–1.4, p < .001). The asso-
ciation with current cocaine use was no longer significant
( p = .1). Findings were similar in analyses that used a cate-
gorical lipohypertrophy outcome (none, mild, and moderate–
severe lipohypertrophy Table 3, model 2). Findings were also
similar in a model focused specifically on belly fat as the
outcome (data not shown) with a similar pattern of findings as
those seen with the categorical lipohypertrophy outcome
shown in Table 3, model 2, except that the association with
current cocaine use did not reach statistical significance.
With regard to lipoatrophy, older age, detectable viral
load, and low current CD4 cell counts were associated with
more severe lipoatrophy using continuous lipoatrophy scores
in adjusted analyses, while African American or black race
was associated with less severe lipoatrophy ( p values <.001–
.008) (Fig. 1). For example, those with a current CD4 cell
count of >350 cells/mm3 had an average lipoatrophy score 1
point lower than those with a CD4 count <200 cells/mm3
(-1.0, 95% CI: -1.2 to -0.7, p < .001). Compared with PLWH
with very low physical activity levels, all other activity lev-
els were associated with less severe lipoatrophy ( p values
<.001).
In a model adjusting for demographic and clinical factors,
current cigarette smoking, marijuana use, and opiate use were
all associated with more severe lipoatrophy ( p values <.001–
.03). In sharp contrast, there was a protective finding for at-
risk alcohol use ( p = .001) (Fig. 1).
The same factors were associated with lipoatrophy as a
binary outcome (any vs. none), but in addition, male sex (OR
1.2: 95% CI 1.0–1.3, p = .03), current ART (OR 1.3: 95% CI
1.1–1.5, p < .001), and methamphetamine use (OR 1.3: 1.1–
1.5, p < .001) were also significantly associated with lipoa-
trophy (Table 4, model 1). Findings were also similar in
adjusted analyses that used a categorical outcome for lipoa-
trophy (none, mild, and moderate–severe lipoatrophy, Table 4,
model 2).
We conducted sensitivity analyses limited to the 10,442
assessments completed by those known to be ART naive
when they enrolled in CNICS. Findings from these sensi-
tivity analyses were similar to those from the entire study
cohort (data not shown). Findings from sensitivity analyses
that also included calendar year were similar to those main
models (data not shown).
Discussion
In this study of 7,931 PLWH from six clinics from across
the United States, we found a high prevalence of body mor-
phology abnormalities: 60% had at least some degree of li-
poatrophy or lipohypertrophy. Most abnormalities were mild,










N = 3,156 N = 2,607 N = 260 N = 1,664 N = 244
N % N % N % p-value* N % N % p-value**
Methamphetamine use
None 2153 68% 1420 55% 159 61% 869 52% 147 60%
Prior 695 22% 886 34% 87 33% 523 31% 68 28%
Current 309 10% 301 12% 14 5% <.001 272 16% 29 12% <.001
Cocaine use
None 1799 57% 1161 45% 138 53% 728 44% 118 48%
Prior 1143 36% 1226 47% 106 41% 780 47% 102 42%
Current 214 7% 220 8% 16 6% <.001 156 9% 24 10% <.001
Opiate use
None 2850 90% 2186 84% 218 84% 1377 83% 203 83%
Prior 244 8% 352 14% 35 13% 227 14% 30 12%
Current 62 2% 69 3% 7 3% <.001 60 4% 11 5% <.001
Marijuana use
None 1296 41% 754 29% 103 40% 446 27% 88 36%
Prior 1019 32% 1049 40% 96 37% 553 33% 74 30%
Current 841 27% 804 31% 61 23% <.001 665 39% 82 34% <.001
Alcohol use
Not at risk 2630 83% 2152 83% 231 89% 1370 82% 211 86%
At-risk 526 17% 455 17% 29 11% .03 294 18% 33 14% .2
Cigarette smoking
None 1301 41% 895 34% 94 36% 494 30% 64 26%
Prior 710 23% 753 29% 74 28% 449 27% 59 24%
Current 1145 36% 959 37% 92 36% <.001 721 43% 121 50% <.001
*Chi2 of no body morphology versus mild lipohypertrophy versus moderate-to-severe lipohypertrophy.
**Chi2 of no body morphology versus mild lipoatrophy versus moderate-to-severe lipoatrophy.
Patients with both lipoatrophy and lipohypertrophy are categorized by the more severe body morphology.
Table 2. Substance Use at Initial Assessment Categorized by Body Morphology (N = 7,931)
lipohypertrophy (4%) or moderate-to-severe lipoatrophy
(3%). Behavioral factors differed in their associations with
lipohypertrophy and lipoatrophy, highlighting the impor-
tance of considering these two distinct outcomes separately
rather than combining them. Prior methamphetamine, co-
caine, and marijuana use and current cocaine use were as-
sociated with more severe lipohypertrophy, although the
impact of each of these individual factors was small. Current
opiate and marijuana use, and current and past cigarette
smoking were all associated with more severe lipoatrophy
in adjusted analyses. Higher physical activity levels were
associated with less severe lipohypertrophy and less severe
lipoatrophy.
Alcohol use
Alcohol use may increase the risk of lipodystrophy based
on a link between alcoholism and the development of ab-
normal fat growth with mitochondrial replication deficits.35
This prior study did not find an association between alcohol
use and lipodystrophy, although there was a possible asso-
ciation between alcohol use and lipohypertrophy.35 Other
studies have also not found associations between alcohol use
and lipodystrophy,5,6,15,36 although few examined the distinct
outcomes of lipohypertrophy and lipoatrophy.5,6 The best
information to date is from FRAM, which did not find as-
sociations between alcohol use and lipohypertrophy mea-
sured by visceral adipose tissue (VAT) or lipoatrophy
measured by leg subcutaneous adipose tissue (SAT).5,6 While
FRAM had a smaller sample size than this study, a FRAM
strength was the rigorous approach to body morphology
measurement.5,6
We found an association between current at-risk alcohol
use and a slight decrease in risk of lipoatrophy, and did not
find an association between at-risk alcohol use and lipohy-
pertrophy. While the association between alcohol use and
lower risk for lipoatrophy is intriguing, this study does not
allow conclusions to be drawn regarding the direction of the
association. It may be that more severe lipoatrophy and as-
sociated factors, including longer duration of HIV infec-
tion, may be leading to less alcohol use rather than the
reverse. Understanding the potential impacts of alcohol
use on body morphology and other outcomes is important
given the high prevalence of at-risk alcohol use among
PLWH.30,37,38
Substance use
General population studies have provided conflicting
findings on the associations between body morphology, BMI,
or body weight status and specific substances with different
findings for past versus current use as well as men versus
women.39–41 Despite this, some substances, such as alcohol,
nicotine, and marijuana potentially impact appetite.42–44
FIG. 1. Mean differences in continuous lipohypertrophy (a) and lipoatrophy (b) scores by demographic, clinical, and
behavioral factors in adjusted analyses.
Table 3. Association Between Demographic, Clinical, and Behavioral
Factors and Lipohypertrophy in Adjusted Analyses












OR, 95% CI, p-value
Sex
Female Ref Ref Ref
Male 0.7; 0.6–0.8, <.001 0.7: 0.7–0.8, <.001 0.3; 0.3–0.4, <.001
Race
White Ref Ref Ref
Black 0.9; 0.8–1.0, .02 0.9; 0.8–1.0, .004 1.2; 0.9–1.5, .3
Hispanic 1.0; 0.9–1.1, .5 0.9; 0.8–1.0, .3 1.3; 1.0–1.7, .07
Other 0.8; 0.6–0.9, .01 0.8; 0.6–1.0, .02 0.9; 0.4–1.7, .7
Age (per year) 1.01; 1.00–1.01, <.001 1.01; 1.00–1.01, <.001 1.01; 1.00–1.02, .1
CD4+ cell count nadir (cells/mm3)
0–200 Ref Ref Ref
201–350 0.8; 0.8–0.9, .006 0.9; 0.8–1.0, .004 0.5; 0.4–0.7, <.001
351 or greater 0.9; 0.8–1.0, .005 0.9; 0.8–1.0, .01 0.8; 0.6–1.0, .07
Current CD4+ cell count (cells/mm3)
0–200 Ref Ref Ref
201–350 1.2; 1.1–1.4, .005 1.2; 1.0–1.3, .03 1.3; 0.9–1.8, .1
351 or greater 1.4; 1.2–1.6, <.001 1.3; 1.2–1.5, <.001 1.5; 1.1–2.1, .01
Current viral load
Detectable Ref Ref Ref
Undetectable 1.2; 1.1–1.3, <.001 1.2; 1.0–1.3, .005 1.2; 1.0–1.6, .1
Current antiretroviral medications
No Ref Ref Ref
Yes 1.2; 1.1–1.4, .001 1.2; 1.0–1.3, .005 1.5; 1.1–2.0, .01
D4T or DDI use (per year) 1.03; 1.01–1.05, .003 1.03; 1.01–1.05, <.001 1.06; 1.01–1.11, .02
Methamphetamine use
None Ref Ref Ref
Prior 1.2; 1.1–1.4, <.001 1.2; 1.1–1.4, <.001 1.0; 0.8–1.4, .8
Current 1.1; 0.9–1.2, .3 1.1; 0.9–1.2, .3 0.6; 0.4–1.0, .04
Cocaine use
None Ref Ref Ref
Prior 1.2; 1.1–1.3, <.001 1.2; 1.1–1.3, .002 1.7; 1.3–2.3, <.001
Current 1.1; 1.0–1.3, .1 1.1; 1.0–1.3, .1 1.6; 1.0–2.6, .03
Opiate use
None Ref Ref Ref
Prior 1.1; 0.9–1.2, .4 1.1; 0.9–1.2, .4 1.1; 0.8–1.5, .5
Current 1.0; 0.8–1.3, .8 1.0; 0.8–1.3, .8 1.2; 0.6–2.4, .7
Marijuana use
None Ref Ref Ref
Prior 1.3; 1.2–1.4, <.001 1.3; 1.2–1.4, <.001 1.2; 0.9–1.5, .2
Current 1.1; 1.0–1.2, .09 1.1; 1.0–1.2, .03 0.8; 0.6–1.1, .2
Cigarette smoking
Never Ref Ref Ref
Prior 1.1; 1.0–1.3, .09 1.2; 1.0–1.3, .005 1.0; 0.8–1.3, .8
Current 0.9; 0.8–1.0, .05 0.9; 0.8–1.0, .08 0.8; 0.6–1.1, .2
Alcohol use
Not at-risk Ref Ref Ref
At-risk 1.1; 1.0–1.2, .2 1.1; 1.0–1.2, .3 0.7; 0.5–0.9, .02
Physical activity level
Very low Ref Ref Ref
Low 0.6; 0.6–0.7, <.001 0.7; 0.6–0.7, <.001 0.4; 0.3–0.4, <.001
Moderate 0.6; 0.6–0.7, <.001 0.6; 0.6–0.7, <.001 0.3; 0.2–0.4, <.001
High 0.4; 0.4–0.5, <.001 0.4; 0.4–0.5, <.001 0.1; 0.1–0.2, <.001
Also adjusted for site, HCV status, and lipoatrophy.
All associations presented are adjusted Odds Ratios.
p values < 0.05 are bolded.
Table 4. Association Between Demographic, Clinical, and Behavioral
Factors and Lipoatrophy in Adjusted Analyses












OR, 95% CI, p-value
Sex
Female Ref Ref Ref
Male 1.2; 1.0–1.3, .03 1.2; 1.0–1.3, .04 0.8 0.6–1.2, .3
Race
White Ref Ref Ref
Black 0.8; 0.7–0.9, <.001 0.8; 0.7–0.9, <.001 0.7; 0.6–1.0, .04
Hispanic 1.0; 0.9–1.2, .4 1.0; 0.9–1.2, .5 1.2; 0.9–1.5, .3
Other 0.7 0.6–0.9, .008 0.7; 0.6–0.9, .008 0.9; 0.5–1.6, .8
Age (per year) 1.02; 1.02–1.03, <.001 1.02; 1.02–1.02, <.001 1.04; 1.03–1.05, <.001
CD4+ cell count nadir (cells/mm3)
0–200 Ref Ref Ref
201–350 1.0; 0.9–1.1, .7 1.0; 0.9–1.1, .6 0.9; 0.7–1.2, .5
351 or greater 1.1; 1.0–1.2, .1 1.1; 1.0–1.3, .06 0.9; 1.6–1.2, .4
Current CD4+ cell count (cells/mm3)
0–200 Ref Ref Ref
201–350 0.8; 0.7–0.9, .001 0.9; 0.8–1.0, .03 0.5; 0.4–0.7, <.001
351 or greater 0.8; 0.7–0.9, <.001 0.9; 0.8–1.0, .03 0.4; 0.3–0.6, <.001
Current viral load
Detectable Ref Ref Ref
Undetectable 0.8; 0.7–0.9, <.001 0.8; 0.7–0.9, .001 0.7; 0.5–0.9, .005
Current antiretroviral medications
No Ref Ref Ref
Yes 1.3; 1.1–1.5, <.001 1.3; 1.2–1.5, <.001 1.1; 0.8–1.5, .5
D4T or DDI use (per year) 1.1; 1.0–1.1, <.001 1.1; 1.0–1.1, <.001 1.1; 1.0–1.1, <.001
Methamphetamine use
None Ref Ref Ref
Prior 1.1; 0.9–1.2, .4 1.1; 0.9–1.2, .4 1.0; 0.7–1.3, 1.0
Current 1.3; 1.1–1.5, <.001 1.4; 1.2–1.6, <.001 0.8; 0.5–1.1, .2
Cocaine use
None Ref Ref Ref
Prior 1.0; 0.9–1.1, .9 1.0; 0.9–1.1, .8 1.0; 0.7–1.3, 1.0
Current 1.1; 0.9–1.2, .6 1.0; 0.9–1.2, .6 1.4; 1.0–2.2, .08
Opiate use
None Ref Ref Ref
Prior 1.1; 1.0–1.2, .2 1.1; 0.9–1.2, .2 1.3; 1.0–1.8, .09
Current 1.3; 1.0–1.7, .02 1.2; 1.0–1.7, .04 2.0; 1.2–3.3, .009
Marijuana use
None Ref Ref Ref
Prior 1.1; 1.0–1.3, .03 1.1; 1.0–1.3, .01 1.0; 0.7–1.3, .8
Current 1.6; 1.4–1.8, <.001 1.6; 1.4–1.8, <.001 1.6; 1.2–2.1, .001
Cigarette smoking
Never Ref Ref Ref
Prior 1.2; 1.0–1.3, .01 1.1; 1.0–1.3, .04 1.5; 1.1–2.0, .008
Current 1.2; 1.1–1.4, <.001 1.2; 1.1–1.3, <.001 1.6; 1.2–2.0, .001
Alcohol use
Not at risk Ref Ref Ref
At-risk 0.9; 0.8–0.9, .002 0.8; 0.7–0.9, <.001 0.7; 0.5–1.0, .05
Physical activity level
Very low Ref Ref Ref
Low 0.7; 0.7–0.8, <.001 0.8; 0.7–0.8, <.001 0.3; 0.3–0.4, <.001
Moderate 0.9; 0.8–1.0, .02 0.9; 0.8–1.0, .2 0.4; 0.3–0.5, <.001
High 0.8; 0.7–1.0, .01 0.9; 0.8–1.1, .2 0.3; 0.2–0.4, <.001
Also adjusted for site, HCV status, and lipohypertrophy.
All associations presented are adjusted Odds Ratios.
p values < 0.05 are bolded.
In HIV-infected populations, one prior study suggested
substance use was not a predictor of regional fat distribu-
tion;36 however, this study was limited to Hispanic individ-
uals and only examined current substance use, not past use.
The authors did not distinguish between current and past use
and did not evaluate individual drugs. Similarly, the FRAM
study did not find associations between substance use and
SAT or VAT.5,6
We found that prior methamphetamine and cocaine use
were associated with lipohypertrophy, while current use of
drugs such as marijuana and illicit opiates/heroin was asso-
ciated with lipoatrophy. While associations between body
morphology and individual drugs were small, it is notable
that these associations are in the setting of adjusting for other
illicit drugs as well as alcohol, smoking, and physical activity
levels. We found key differences between associations of
individual drugs with either lipohypertrophy or lipoatrophy.
Our results reinforce the importance of examining the impact
of drug use separately for each outcome.
Smoking
There are limited studies examining associations between
smoking and lipohypertrophy and lipoatrophy. One small
study did not find an association between smoking and li-
podystrophy.15 The FRAM study found an association be-
tween being a current smoker and less lipohypertrophy as
measured by VAT, but did not find an association between
being a current smoker and lipoatrophy as measured by
SAT.5,6 Another small study among Hispanic patients36
found current smokers had less truncal fat consistent with our
findings that current smoking was associated with less severe
lipohypertrophy. The prior study of Hispanic patients also
found that among males, current smokers had more appen-
dicular fat.36 In contrast, we found that in analyses that
also took into account substance and alcohol use, the current
and past smoking were both associated with more severe
lipoatrophy.
Physical activity
Prior studies often focused on lipodystrophy rather than
lipohypertrophy and lipoatrophy. They found associations
between physical activity level and lipodystrophy,15,45 but
were small studies unable to look at the simultaneous impact
of physical activity and other behavioral factors.45 An early
trial of patients on indinavir, lamivudine, and either stavudine
or zidovudine found that the absence of physical activity was
associated with developing lipoatrophy, but not lipohyper-
trophy.46 Other studies found a relationship between physical
activity and lack of central fat accumulation47 and moderate
physical activity and waist circumference.48 The FRAM
study found an association between physical activity quartile
and less SAT and VAT among men, and a suggestion of an
association between physical activity and SAT, but not VAT
among women.5,6
Our findings demonstrated associations between higher
physical activity levels and both decreased lipohypertrophy
and lipoatrophy across the spectrum of physical activity
levels even when adjusting for other key behavioral factors
that are often associated with physical activity levels. These
findings suggest a possible protective association for higher
levels of physical activity.
Measurement or scoring of lipohypertrophy
and lipoatrophy
Self-reported body morphology abnormalities have been
scored in several ways, including as binary, categorical, and
continuous outcomes.49–53 Few comparisons have been made
between approaches. Categorizing or dichotomizing out-
comes can be advantageous for improving interpretability
and ease of describing results. However, loss of information
and loss of power have been described for dichotomizing or
categorizing continuous data.54
We found differences using three scoring approaches, for
example, current cocaine use was associated with lipohy-
pertrophy when using the continuous and categorical ap-
proaches, but not binary, and the association between current
ART use and lipohypertrophy was significant only with cat-
egorical and binary scoring, although the size of the associ-
ation was also similar and suggestive to using continuous
scoring. While differences existed, the pattern of findings was
consistent for most associations across the three approaches.
Furthermore, given the small differences in associations be-
tween scoring approaches, but the large differences in the as-
sociations between lipohypertrophy versus lipoatrophy, these
findings suggest that differences in scoring approaches for li-
pohypertrophy and lipoatrophy have an impact, but that it is
much smaller than the misclassification, loss of information,
and potential erroneous conclusions that can be made by
combining lipohypertrophy and lipoatrophy into one outcome.
Strengths
A study strength was the assessment of individual illicit
drug use, including current and past use in adjusted models
that simultaneously consider other drugs, alcohol use, ciga-
rette use, and physical activity levels. Drug use is often as-
sociated with other harmful behaviors such as smoking and
alcohol use. The large sample size and comprehensive clin-
ical data available, including information from the CNICS
clinical assessment, facilitated examining the associations
of these behaviors simultaneously. Use of the FRAM body
morphology measure was an additional strength allowing us
to examine both independent effects of lipohypertrophy and
lipoatrophy as well as differences by the severity of body
morphology abnormality. An advantage of FRAM assess-
ments over DEXA scans or single-cut CT scans is that FRAM
allows facial lipoatrophy changes to be included.
Limitations
A limitation of this study is the relevance of body mor-
phology abnormalities, particularly lipoatrophy in the current
ART era. However, while key risk factors such as stavudine
are rarely, if ever, used in care currently, many PLWH have
now been alive and in care for many years. The percentage
reporting lipoatrophy (mild or moderate-to-severe) in care in
CNICS in 2015 (22%) was similar to the percentage in the
study overall as shown in the results section (23%), sug-
gesting that understanding these associations and mecha-
nisms is still relevant in the current treatment era. Our study
design precluded us from drawing conclusions regarding
causality. We suspect that lower physical activity levels lead
to increased risk of body morphology abnormalities; how-
ever, longitudinal studies are needed to elucidate these
relationships. Associations with lipohypertrophy can be
complicated by misclassification and overlap with obesity.
We do not address whether associations are due to direct
effects of illicit drugs versus indirect effects, such as by
changes in appetite. We focused on current alcohol use; all
nondrinkers were a single group, including people who were
never at-risk alcohol drinkers and people with prior at-risk
alcohol use who became nondrinkers.55,56 Additional studies
are needed that parse these nuances before the potential im-
pact of alcohol use on body morphology among PLWH can
be well understood. An additional limitation is the potential
for Type 1 errors when evaluating multiple covariates with
two outcomes each of which has three parameterizations.
Patterns of association that are similar across the three
parameterizations provide some reassurance that those as-
sociations are less likely due to Type 1 errors. Finally, while
the self-reported morphology assessment included in this
study allowed inclusion of facial changes, MRI-based depot
measures provide slightly different results.5,6 Self-reported
morphology results are closer to the perceived clinical syn-
drome. However, the differences between these results may
shed light on how drug use affects perception as well as
adipose tissue.
Conclusions
We found a high prevalence of lipohypertrophy and li-
poatrophy among this nationally distributed clinical cohort of
PLWH, although most of these abnormalities were mild.
Behavioral factors differed in their associations with lipo-
hypertrophy and lipoatrophy. Prior methamphetamine, co-
caine, and marijuana use and current cocaine use were
associated with more severe lipohypertrophy. Current opiate
and marijuana use, and current and past smoking were all
associated with more severe lipoatrophy. While low levels of
physical activity are associated with both lipohypertrophy
and lipoatrophy, associations with substance use and other
clinical characteristics differed between lipohypertrophy and
lipoatrophy. These results support the conclusion that lipo-
hypertrophy and lipoatrophy are distinct and should be ex-
amined separately rather than combined. These results also
highlight the importance of examining the impact of drug use
by an individual class of drug. These results may prove useful
in counseling patients who wish to avoid body morphology
changes and further our understanding of associations with
these conditions and their possible mechanisms.
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